Twist Bioscience Corp (TWST) Form 424B5 — Aug 5, 2026

$TWSTForm 424B5Filed Aug 5, 2026, 4:48 PM ET0001104659-26-091202Original filing

Twist Bioscience has priced a follow-on public offering of 3,125,000 shares of common stock at $96.00 per share, targeting gross proceeds of $300 million and expected net proceeds of approximately $284.3 million. Underwriters hold a 30-day option to purchase up to 468,750 additional shares, which would lift net proceeds to approximately $327.1 million. The deal is led by Goldman Sachs & Co. LLC with William Blair, Leerink Partners and Guggenheim Securities as co-underwriters, with share delivery expected on or about August 6, 2026.

Key figures

Eps: -$0.56 (Q3 FY2026 diluted)
Revenue: $118.4 million (Q3 FY2026, three months ended June 30, 2026)
Net Income: -$35.1 million (Q3 FY2026 net loss)
Gross Proceeds: 300000000
Offering Price: 96
Shares Offered: 3125000
Shares Outstanding: 65,799,150 after offering (66,267,900 if greenshoe fully exercised; 62,674,150 before, as of June 30, 2026)
Net proceeds: $284.3 million ($327.1 million if greenshoe exercised in full)
Greenshoe shares: 468750
Lockup period days: 60
Adjusted ebitda q3 fy2026: -$11.3 million
Q3 fy2026 interest income: $1.5 million
Estimated offering expenses: $0.7 million
Total underwriting discount: $15.0 million ($17.25 million with full greenshoe exercise)
Immediate dilution per share: 86.35
Atm program remaining capacity: $200.0 million (no shares sold to date, TD Securities Sales Agreement dated June 18, 2026)
Underwriting discount per share: 4.8
Last reported sale price aug 4 2026: 99.44
Q3 fy2026 depreciation and amortization: $6.778 million
Pro forma net tangible book value per share: 9.65
Net tangible book value per share pre offering: 5.6

Price after filing

1 day: -5.2%7 days: +8.9%30 days: +11.9%

Close on the filing date to close N calendar days later (from $115.01). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.